Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28,027,744
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
14,366,664
-
Shares change
-
-564,093
-
Total reported value, excl. options
-
$86,200,310
-
Value change
-
-$4,439,158
-
Put/Call ratio
-
51.62%
-
Number of buys
-
32
-
Number of sells
-
-34
-
Price
-
$6
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q4 2021
83 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q4 2021.
NextCure, Inc. - Common Stock (NXTC) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14,366,664 shares
of 28,027,744 outstanding shares and own 51.26% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (2,711,013 shares), Sofinnova Investments, Inc. (2,671,856 shares), BlackRock Inc. (1,242,133 shares), MILLENNIUM MANAGEMENT LLC (1,007,988 shares), Woodline Partners LP (755,996 shares), VANGUARD GROUP INC (751,569 shares), FEDERATED HERMES, INC. (525,540 shares), Lombard Odier Asset Management (Switzerland) SA (407,291 shares), CITADEL ADVISORS LLC (393,636 shares), and GOLDMAN SACHS GROUP INC (333,128 shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.